Related Experiment Video
Updated: Jul 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction
Objective:
Assess efficacy, safety, and cost of alternate-day dosing with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (HRIs).
Data:
International Pharmaceutical Abstracts and MEDLINE (English-language clinical trials, 1966-April 2000) were searched.
Data Synthesis:
Established efficacy of HRIs is based on daily administration. Many patients who could benefit from these agents are unable to afford them; therefore, alternate-day dosing may be a solution for reducing expense without decreasing therapy benefits. Studies addressing alternate-day HRI therapy are evaluated to determine the usefulness of this option for cholesterol reduction.
Conclusions:
Although limited studies imply a trend toward benefit with alternate-day HRI therapy, large, controlled, randomized trials are needed before making this a standard recommendation.
Related Concept Videos
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Dosage Regimen: Multiple Oral Dosage
Atherosclerosis III: Management

